Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers

Abstract Background HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about its association with outcomes of chemotherapy. The aim of this study w...

Full description

Bibliographic Details
Main Authors: Yan Wang, Shijia Zhang, Fengying Wu, Jing Zhao, Xuefei Li, Chao Zhao, Shengxiang Ren, Caicun Zhou
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Cancer
Subjects:
HER2 mutation
Lung adenocarcinoma
Pemetrexed
Online Access:http://link.springer.com/article/10.1186/s12885-018-4277-x

Similar Items

Similar Items